Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HCT for T-cell Proliferation and Dysregulation Disorders
NCT03663933Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic hematopoietic stem cells in T-cell proliferation and dysregulation disorders, sponsored by National Cancer Institute. Started Sep 2018; status: active, not recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
T-cell proliferation and dysregulation disorders
Beyond the preview
Go deeper on NCT03663933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663933.